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  Bronchiolitis obliterans syndrome(BOS) is an important complication after 
hematopoietic stem cell transplantation(HSCT). Recent observations suggested that 
azithromycin might improve lung function in BOS after HSCT. We conducted a 
randomized double-blinded placebo-controlled study on azithromycin in patients with 
BOS after HSCT. Treatment group(n = 10) received oral azithromycin 250mg daily 
while control group(n = 12) received placebo daily for 12 weeks. Respiratory 
symptoms were assessed by the St George Respiratory Questionnaires and spirometry 
at baseline(drug commencement), one month, two months, three months(drug 
cessation) and four months(one month after drug cessation). There was no significant 
difference in the baseline demographic characteristics between the treatment and the 
control group in age, gender, time from HSCT to BOS, time since diagnosis of BOS, 
chronic graft versus host disease(cGVHD), baseline respiratory symptom scores and 
baseline forced expiratory volume in one second(FEV1). Throughout and after three 
months of treatment, there were no significant changes in respiratory symptom scores 
and FEV1 measurements between the treatment and the control group. In conclusion, 
there was no significant benefit of three months of oral azithromycin on the 
respiratory symptoms and lung function in patients with relatively late BOS after 




  Bronchiolitis obliterans syndrome (BOS) is an important pulmonary 
complication after hematopoietic stem cell transplantation (HSCT) for treatment of 
both acute and chronic leukemias as well as aplastic anemia (1). BOS usually 
develops as a late complication after HSCT (after the first 100 days 
post-transplantation) and is believed to be part of the chronic graft versus host disease 
(cGVHD) phenomenon (2-4). BOS can also occur after lung transplantation, in which 
case it is a manifestation of chronic graft rejection (5), although the underlying 
mechanism has not completely been identified (6). 
  BOS may be the result of immunologic injury targeting both endothelial and 
epithelial tissues in the pulmonary system, and such immunologic damage may 
represent cGVHD, or can be induced and aggravated by non-alloimmunologic 
inflammation associated with bacterial and viral infections (7), or silent chronic 
aspiration from gastro-esophageal reflux (8). 
  The mainstay of therapy for BOS after HSCT is treatment of chronic 
GVHD with augmentation of immunosuppression (9). Previous experience with BOS 
after lung transplantation has suggested a possible anti-inflammatory role for 
macrolides (10). Treatment with oral azithromycin for a median of ten months has 
been shown in various series of observational and retrospective studies in lung 
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transplant recipients with BOS to slow progression (11), and improve pulmonary 
function (12-14). However, a recent prospective study of maintenance azithromycin 
has shown no significant effects on the forced expiratory volume in one second (FEV1) 
in lung transplant recipients with BOS (15). A beneficial effect of azithromycin on 
lung functions in BOS patients after HSCT has also been shown (16, 17). Therefore, 
the role of azithromycin in BOS after HSCT requires more rigorous appraisal. 
 
Materials and methods 
Patient recruitment criteria. Adult patients (> 18 years of age) who had undergone 
HSCT (allogeneic and autologous) at Queen Mary Hospital, Hong Kong, were 
eligible for inclusion. Patients with known allergy to macrolides or with other obvious 
reasons for pulmonary function decline such as infection or airway complications 
were excluded. Patients on long term macrolides were also excluded. The pulmonary 
function criteria for defining BOS were (i) FEV1 < 75% predicted, with FEV1/FVC 
ratio of < 0.70, and (ii) a reduction of FEV1 by more than 10%, compared to the 
corresponding baseline values at time of HSCT, as modified from NIH criteria but 
air-trapping was not an inclusion criteria (7, 18). Spirometry parameters were 
measured with reference to Ip MS et al for the local Hong Kong subjects (19). 
Histopathological proof was required. The trial was registered with the Clinical Trial 
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Center, University of Hong Kong Hospital Authority Hong Kong West Cluster. 
Informed written consent was obtained from each patient before recruitment. 
Study design. This was a randomized double-blinded placebo-controlled study. 
Recruited subjects were randomized to receive oral Azithromycin 250mg daily 
(Zithromax®, Pfizer) (treatment group) or placebo (one tablet daily) (Control group) 
for 12 weeks. All subjects received trial treatment in addition to their usual 
immunosuppressive regimen within the study period. Clinical assessments were done 
at baseline (drug commencement), 4 weeks, 8 weeks, 12 weeks (drug cessation) and 
16 weeks (4 weeks after drug cessation) with spirometries and respiratory symptom 
assessment by the St George Respiratory Questionnaires (SGRQ)(20) at each visit. 
The SGRQ collected information on the subjects’ respiratory symptoms, impact on 
physical functions and daily activities. The primary endpoint was respiratory 
symptoms as assessed by the SGRQ at four months. The secondary endpoint was 
spirometry parameters at four months. Additional spirometric assessments were 
performed at 6 and 12 months. The presence of chronic GVHD was recorded and 
severity graded according to the International Bone Marrow Transplant Registry 
(IBMTR) severity scoring (21) into mild, moderate and severe. 
Statistical analyses. Comparisons between the treatment and placebo groups were 
made with respect to their demographic characteristics (age, gender, smoking history), 
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baseline spirometric parameters and percentage change at 3 months, and baseline St 
George Respiratory Questionnaire Scores (respiratory symptoms, impact of 
respiratory symptoms on daily life, activities and overall scores) and the score 
changes at 3 months. Student t tests and Mann Whitney U tests (non-parametric) were 
applied where appropriate. SPSS 15.0 was used for statistical calculations. 
 
Results 
Patients. From 1 April, 2006 to 30 December, 2007, 24 consecutive patients were 
recruited and randomized into either the treatment group (n = 12) or the placebo group 
(n = 12). There was no significant difference between the treatment and control group 
in terms of mean age (43.5 ± 8.6 vs 42.4 ± 9.2 years, p = 0.779), gender ratio, cGVHD 
grading (p = 0.410), mean Karnofsky performance score (p = 0.650), time from HSCT 
to inclusion (5.8 ± 4.0 vs 7.0 ± 3.3 years, p = 0.448) and time between BOS diagnosis 
to inclusion (4.3 ± 3.2 vs 5.8 ± 4.2 years, p = 0.359). Two patients from the treatment 
group withdrew from the study after recruitment and randomization. One of them 
complained of dyspepsia after taking 8 days of study drug and requested withdrawal 
from the study. The other patient, having taken 3 weeks of study drug, was admitted 
for pneumothorax, after which the patient withdrew from the study. Thus ten and 
twelve subjects completed the study in the treatment group and control group 
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respectively (Table 1). 
Results. There was no significant difference in the baseline FEV1 between the 
treatment and control group. There appeared to be worsening of lung function 
parameters in the treatment group compared with the control group, although the 
difference were not statistically significant (Table 2). There was also a consistent 
increase in the Respiratory Symptom scores but a consistent decrease in the Impact 
scores, Activities scores and Total scores in St George Respiratory Questionnaires 
(Table 3) assessment in the treatment group compared with the control group, 
although the difference was not statistically significant. 
 
Discussion 
  This was the first randomized double-blinded placebo-controlled study on 
the effects of oral azithromycin on patients with BOS after HSCT. 
The anti-inflammatory actions of azithromycin are thought to be mediated 
via action on neutrophils and cytokines especially interleukin-8 in early BOS in lung 
transplant recipients (22). Azithromycin also possesses antimicrobial actions against 
chlamydia and mycoplasma, although these may not be strong with the dosage of 
250mg daily as used in the current study (23). It would be difficult to predict or 
ascertain whether azithromycin is acting through its anti-inflammatory actions on the 
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alloimmune system or its alternative mechanisms of action in BOS, as the underlying 
pathogenesis is not yet completely understood and these clinical studies on 
azithromycin were performed in lung transplant recipients (22, 23). 
Although there were previous reports of favorable effects of azithromycin 
on the lung function of patients with BOS after HSCT (16) and lung transplantation 
recipients (24), similar favorable effects of azithromycin could not be demonstrated in 
our patients with BOS after HSCT in this study. This might reflect that the basic 
mechanisms underlying BOS in HSCT could be different from BOS after lung 
transplantation (2). In lung transplantation, BOS probably represents the direct 
rejection of donor organs (10); while in HSCT, BOS might represent part of the 
cGVHD, which could also involve the skin, gastrointestinal tract and liver (9). The 
risk factors for development of BOS after HSCT are also different from lung 
transplantation (25). The pathogenesis of post-transplant airflow obstruction after 
HSCT is hypothesized to be due to donor cytotoxic T lymphocytes targeting and 
attacking bronchiolar and other epithelial cells as part of cGVHD (9, 26) although this 
has not been confirmed in animal model or human subjects. However, the situation in 
lung transplant recipients was more clearly defined. There is augmentation of HLA 
class I and II antigens on lung endothelial and epithelial cells, and the involvement of 
recipient cytotoxic T lymphocyte in the airway via the release of proinflammatory 
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cytokines in the lung graft (27, 28). Another potential issue in post-transplant airflow 
obstruction is the presence of recurrent aspiration and unrecognized viral infection, 
both of which has been reported in lung transplantation (8), but similar possibility has 
not been documented in HSCT patients or in this study. Furthermore, BOS subjects in 
other studies (16) that reported benefits of azithromycin tended to be recruited 
immediately or soon after the diagnosis of BOS whereas in this study, the subjects 
recruited had BOS established for a few years, and this might account for the apparent 
non-responsiveness of patients to azithromycin. The fact that there was no significant 
improvement in respiratory symptoms and spirometry function may represent a 
therapeutic benefit of sustaining a stable state in BOS patients. However, this cannot 
be proven with this short term randomized-control trial. 
  During the study period, there was no significant change in the condition 
and immunosuppressant regimen. Also, there was no significant worsening in cGVHD 
profiles that warranted change of immunosuppressant regimen. However, the baseline 
cGVHD grades in the treatment group appeared to be slightly more severe than in the 
control group, although the difference was not statistically significant. This might 
contribute to the mild non-significant degree of worsening of lung function 
parameters and respiratory symptoms observed in the treatment group. 
  This study has a number of limitations. Only a relatively small number of 
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patients (22 BOS subjects) had been recruited, owing to the relative rarity of BOS as a 
post-HSCT complication. The diagnosis of BOS after HSCT is usually a clinical 
diagnosis based on symptoms and spirometric parameters (7). We would also like to 
emphasize that the study was done on late BOS patients, though we did not aim at 
selecting them for recruitment, which may make the condition very chronic and any 
changes in symptoms and lung functions slow to occur. The dosage of azithromycin 
(250mg daily for 12 weeks) used in this study, however, was different from the usual 
dose employed in clinical trials in lung transplant recipients and HSCT subjects 
(250mg 3 times per week for 12 weeks) (12, 16). Spirometry only was used as 
secondary endpoint measurement for this study, and lung volumes and diffusion 
factors were not measured. The presence of restriction may in turn affect the FEV1 
and FVC measurement. The previous use of bulsulphan in some of the recruited 
subjects could result in subsequent development of pulmonary toxicity with impaired 
diffusion capacity or combined restrictive component. However, subsequent followed 
up of all the subjects did not reveal clinical pulmonary toxicity and full lung function 
tests were not performed. Baseline CT Thorax and bronchoalveolar lavage were not 
performed as they were considered invasive investigation and underlying pulmonary 
infection resulting in lung function abnormality cannot be completely ruled out. We 
can only assumed that clinically significant pulmonary infection was not present as 
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subsequent follow up of these subjects up to one year after study did not show 
development of pulmonary infection. Histological proof for BOS was not available, 
mainly because of impaired lung function that made invasive procedures such as 
transbronchial biopsy or open lung biopsy unsafe in these subjects. Pathological 
diagnosis of BOS, if possible, could better characterize BOS in HSCT patients, and 
could allow better correlations of clinical response to therapeutics with therapeutics to 
be made. Three months of Azithromycin, however, could be too short for any 
BOS-related changes to occur. This small study should serve as the basis for a better 
balanced and multi-centered controlled study about this important issue. 
 
Conclusion 
  We concluded that in this randomized placebo-controlled trial on 
azithromycin in patients with relatively late BOS after HSCT, no improvement of 
respiratory symptoms and lung function occurred after three months of treatment. 
Further studies with larger number of subjects, especially targeting the use of 
azithromycin in the early phase of BOS, may give more definitive results on its 
potential role in the treatment of BOS post-HSCT, which remains a rather refractory 
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Table 1 Characteristics of recruited subjects 
 
Patients with code starting with ‘A-‘ were in the treatment group, those with ‘P-‘ were in the Placebo group 
M = males, F = females; NS = non-smoker, EX = ex-smoker; CML = chronic myeloid leukemia, DLBC = Diffuse large B cell lymphoma, AML 
= acute myeloid leukemia, NHL = non-Hodgkin’s lymphoma, MDS = myelodysplastic syndrome, SAA = severe aplastic anemia; BMT = bone 
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marrow transplantation, BO = bronchiolitis obliterans; CT = computed tomography; KPS = Karnofsky Performance Score; Wt loss = weight 
loss; NA = presentation so minor that it was regarded as absent 
Bu = Busulphan, Cy = Cyclophosphamide, TBI = Total body irradiation; Degree of HLA-matching: 6 Antigen Matching with HLA-A, -B 
and –DR for matched sibling; up to 8 Antigen Matching with HLA-A, -B, -C and –DR for unrelated donor; Sib = matched sibling, UD = 
unrelated donor; CSP = cyclosporine, IVIG = intravenous immunoglobulin, MMF = mycophenolate mofetil, FK506 = Tacrolimus. 
CEOP = Cyclophosphamide+Epirubicin+Vincristine+Prednisolone; 
DHAP = Cisplatin+Cytarabine+Dexamethasone; 
R-CEOP = Mabthera+Cyclophosphamide+Epirubicin+Vincristine+Prednisolone; 
IMVP = Ifosfamide+Methotrexate+Etoposide; 
MiniBEAM = Carmustine+Etoposide+Cytarabine+Melphalan; 
VAD = Vincristine+Adriamycin+Dexamethasone; 
CVP = Cyclophosphamide+Vincristine+Prednisolone; 














Table 2 Comparisons of baseline spirometric parameters and changes after treatment between the treatment group and the control group 
      Treatment  Control   Significance 
Baseline Mean FEV1 (L) 1.44 ± 0.57  1.52 ± 0.60  0.746 
Mean FEV1 (L)   
 At 1 month   1.43 ± 0.59  1.48 ± 0.61  0.860 
 At 2 month   1.41 ± 0.64  1.53 ± 0.67  0.650 
 At 3 month   1.43 ± 0.58  1.62 ± 0.72  0.510 
 At 4 month   1.44 ± 0.61  1.54 ± 0.66  0.726 
Mean FEV1 % change   
 At 1 month   - 0.67 ± 8.78  - 2.14 ± 12.15  0.751 
 At 2 month   - 3.41 ± 14.02  + 0.95 ± 13.72  0.473 
 At 3 month   - 0.47 ± 13.57  + 6.11 ± 15.02  0.293 
 At 4 month   - 1.21 ± 13.09  + 0.74 ± 10.79  0.711 
Baseline Mean FVC (L) 2.86 ± 0.67  3.07 ± 0.86  0.525 
Mean FVC (L)  
 At 1 month   2.83 ± 0.71  3.11 ± 0.89  0.403 
 At 2 month   2.89 ± 0.68  3.03 ± 0.91  0.674 
 At 3 month   2.91 ± 0.72  3.12 ± 0.92  0.554 
 At 4 month   2.94 ± 0.74  3.05 ± 0.86  0.757 
Mean FVC % change   
 At 1 month   - 1.27 ± 7.97  1.97 ± 8.49  0.369 
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 At 2 month   1.13 ± 8.40  - 1.34 ± 6.70  0.462 
 At 3 month   1.73 ± 10.0  1.61 ± 7.23  0.974 
 At 4 month   2.79 ± 8.88  - 0.37 ± 5.62  0.345 
Baseline Mean FEF25-75% 1.56 ± 3.13  0.68 ± 0.52  0.402 
Mean FEF25-75% (L) 
 At 1 month   0.61 ± 0.43  0.65 ± 0.40  0.804 
 At 2 month   0.64 ± 0.45  0.78 ± 0.77  0.583 
 At 3 month   0.61 ± 0.38  0.85 ± 0.92  0.424 
 At 4 month   0.60 ± 0.34  0.72 ± 0.59  0.576 
Mean FEF25-75% % change 
 At 1 month   - 19.79 ± 44.35 + 13.92 ± 54.79 0.126 
 At 2 month   - 40.32 ± 129.20 + 5.85 ± 20.55  0.291 
 At 3 month   - 6.30 ± 34.08  + 22.85 ± 46.13 0.105 













Table 3 Comparisons of St George Respiratory Questionnaire Scores between the  treatment group and the control group 
      Treatment  Control   Significance 
Symptom scores (baseline) 56.2 ± 30.8  57.1 ± 18.1  0.223 
% change in symptom scores 
 At 1 month   + 2.1 ± 10.6  + 3.0 ± 18.0  0.582 
 At 2 month   + 0.6 ± 7.0  - 0.1 ± 14.5  0.821 
 At 3 month   + 2.3 ± 15.4  - 5.6 ± 16.8  0.711 
 At 4 month   + 4.2 ± 25.5  + 0.7 ± 10.8  0.628 
 
Impact scores (baseline) 37.2 ± 21.0  32.0 ± 24.2  0.113 
% change in Impact scores 
 At 1 month   - 14.9 ± 29.5  - 3.5 ± 34.8  0.539 
 At 2 month   - 12.6 ± 31.5  + 1.4 ± 47.2  0.722 
 At 3 month   - 11.1 ± 46.6  - 6.2 ± 42.9  0.923 
 At 4 month   - 18.6 ± 39.9  + 21.0 ± 75.5  0.283 
 
Activity scores (baseline) 56.8 ± 25.2  44.8 ± 22.4  0.125 
% change in Activity scores 
 At 1 month   - 10.9 ± 21.0  + 2.8 ± 17.2  0.582 
 At 2 month   - 5.3 ± 23.6  + 16.6 ± 49.8  0.821 
 At 3 month   - 7.3 ± 26.0  + 25.0 ± 65.9  0.283 
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 At 4 month   - 17.0 ± 37.4  + 21.0 ± 78.6  0.093 
 
Total scores (baseline)  46.3 ± 19.5  40.0 ± 20.2  0.542 
% change in Total scores 
 At 1 month   - 10.8 ± 20.5  -0.2 ± 17.3  0.381 
 At 2 month   - 7.3 ± 22.7  + 5.1 ± 31.5  0.923 
 At 3 month   - 8.8 ± 30.0  + 1.3 ± 23.9  0.628 
 At 4 month   - 14.6 ± 32.8  + 7.6 ± 40.5  0.314 
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